Cale D. Fahrenholtz

696 total citations
24 papers, 530 citations indexed

About

Cale D. Fahrenholtz is a scholar working on Pulmonary and Respiratory Medicine, Biomedical Engineering and Biomaterials. According to data from OpenAlex, Cale D. Fahrenholtz has authored 24 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Biomedical Engineering and 6 papers in Biomaterials. Recurrent topics in Cale D. Fahrenholtz's work include Nanoplatforms for cancer theranostics (7 papers), Nanoparticle-Based Drug Delivery (6 papers) and Prostate Cancer Treatment and Research (6 papers). Cale D. Fahrenholtz is often cited by papers focused on Nanoplatforms for cancer theranostics (7 papers), Nanoparticle-Based Drug Delivery (6 papers) and Prostate Cancer Treatment and Research (6 papers). Cale D. Fahrenholtz collaborates with scholars based in United States. Cale D. Fahrenholtz's co-authors include Ravi Singh, Kerry L. Burnstein, Brian W. Bernish, Jessica Swanner, Pedro J. Beltran, George L. Donati, Suzy V. Torti, Ferenc G. Rick, Andrew V. Schally and S. Bruce King and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Cale D. Fahrenholtz

23 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cale D. Fahrenholtz United States 13 205 187 131 123 119 24 530
April D. Harrison United States 11 180 0.9× 272 1.5× 106 0.8× 97 0.8× 65 0.5× 13 599
Zhongqian Hu China 17 494 2.4× 294 1.6× 164 1.3× 142 1.2× 99 0.8× 31 839
Diane Marotta United States 12 134 0.7× 262 1.4× 69 0.5× 49 0.4× 118 1.0× 16 577
Chien‐Hsiu Li Taiwan 15 136 0.7× 258 1.4× 110 0.8× 78 0.6× 59 0.5× 37 543
Yongju Gao China 12 172 0.8× 103 0.6× 105 0.8× 76 0.6× 79 0.7× 29 427
Jinjie Chang China 10 331 1.6× 173 0.9× 201 1.5× 77 0.6× 145 1.2× 14 629
Meng-jun Qiu China 13 188 0.9× 174 0.9× 111 0.8× 70 0.6× 102 0.9× 28 535
Shruti Shah United States 11 252 1.2× 258 1.4× 38 0.3× 247 2.0× 28 0.2× 31 620

Countries citing papers authored by Cale D. Fahrenholtz

Since Specialization
Citations

This map shows the geographic impact of Cale D. Fahrenholtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cale D. Fahrenholtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cale D. Fahrenholtz more than expected).

Fields of papers citing papers by Cale D. Fahrenholtz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cale D. Fahrenholtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cale D. Fahrenholtz. The network helps show where Cale D. Fahrenholtz may publish in the future.

Co-authorship network of co-authors of Cale D. Fahrenholtz

This figure shows the co-authorship network connecting the top 25 collaborators of Cale D. Fahrenholtz. A scholar is included among the top collaborators of Cale D. Fahrenholtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cale D. Fahrenholtz. Cale D. Fahrenholtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Swanner, Jessica, et al.. (2021). Combined Photothermal and Ionizing Radiation Sensitization of Triple-Negative Breast Cancer Using Triangular Silver Nanoparticles. International Journal of Nanomedicine. Volume 16. 851–865. 32 indexed citations
5.
Zhao, Ning, Chen Hao Lo, Meghan A. Rice, et al.. (2019). Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science Translational Medicine. 11(498). 41 indexed citations
6.
Swanner, Jessica, Cale D. Fahrenholtz, Iliana Tenvooren, et al.. (2019). Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo. FASEB BioAdvances. 1(10). 639–660. 69 indexed citations
7.
8.
Fahrenholtz, Cale D., et al.. (2017). Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin. Journal of Nanomaterials. 2017. 1–11. 46 indexed citations
9.
Fahrenholtz, Cale D., Song Ding, Brian W. Bernish, et al.. (2016). Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. Journal of Inorganic Biochemistry. 165. 170–180. 14 indexed citations
10.
Bernish, Brian W., et al.. (2016). Photothermal Therapy of Glioblastoma Multiforme Using Multiwalled Carbon Nanotubes Optimized for Diffusion in Extracellular Space. ACS Biomaterials Science & Engineering. 2(6). 963–976. 67 indexed citations
11.
Fahrenholtz, Cale D., et al.. (2016). Abstract B05: Self-assembling platinum-acridine loaded carbon nanotubes for triple-negative breast cancer chemotherapy. Molecular Cancer Research. 14(2_Supplement). B05–B05. 3 indexed citations
12.
Fahrenholtz, Cale D., Mallinath B. Hadimani, S. Bruce King, Suzy V. Torti, & Ravi Singh. (2015). Targeting Breast Cancer with Sugar-Coated Carbon Nanotubes. Nanomedicine. 10(16). 2481–2497. 33 indexed citations
13.
Fahrenholtz, Cale D., Ferenc G. Rick, Márta Zarándi, et al.. (2014). Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences. 111(3). 1084–1089. 51 indexed citations
14.
Fahrenholtz, Cale D., et al.. (2014). A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget. 5(19). 9007–9021. 7 indexed citations
15.
Rick, Ferenc G., et al.. (2014). Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer.. Journal of Clinical Oncology. 32(4_suppl). 221–221. 1 indexed citations
16.
Fahrenholtz, Cale D., Pedro J. Beltran, & Kerry L. Burnstein. (2013). Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts. Molecular Cancer Therapeutics. 12(4). 394–404. 27 indexed citations
17.
Fahrenholtz, Cale D., et al.. (2012). Abstract 2148: Exploitation of androgen receptor splice variant signaling by guanine nucleotide exchange factor Vav3 in castration resistant prostate cancer. Cancer Research. 72(8_Supplement). 2148–2148. 1 indexed citations
18.
Rao, Shuyun, Leah Lyons, Cale D. Fahrenholtz, et al.. (2011). A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 31(6). 716–727. 38 indexed citations
19.
Fahrenholtz, Cale D., Pedro J. Beltran, Frank J. Calzone, & Kerry L. Burnstein. (2011). Abstract C55: Ganitumab (AMG 479) inhibits the development and progression of castration-resistant VCaP human prostate cancer xenografts.. Molecular Cancer Therapeutics. 10(11_Supplement). C55–C55. 1 indexed citations
20.
Larsen, Eric, Yoichi Kondo, Cale D. Fahrenholtz, & Ian D. Duncan. (2008). Generation of Cultured Oligodendrocyte Progenitor Cells from Rat Neonatal Brains. Current Protocols in Stem Cell Biology. 6(1). Unit 2D.1.1–2D.1.13. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by April D. Harrison Breakdown of academic impact, for papers by Zhongqian Hu Breakdown of academic impact, for papers by Diane Marotta Breakdown of academic impact, for papers by Chien‐Hsiu Li Breakdown of academic impact, for papers by Yongju Gao Breakdown of academic impact, for papers by Jinjie Chang Breakdown of academic impact, for papers by Meng-jun Qiu Breakdown of academic impact, for papers by Shruti Shah
Rankless by CCL
2026